Unique ID issued by UMIN | UMIN000016913 |
---|---|
Receipt number | R000019630 |
Scientific Title | Phase II trial of gemcitabine/cisplatin/s1 for inoperable biliary tract cancer |
Date of disclosure of the study information | 2015/04/01 |
Last modified on | 2019/03/28 09:47:01 |
Phase II trial of gemcitabine/cisplatin/s1 for inoperable biliary tract cancer
Chemotherapy for the patients with inoperable biriary tract cancer
Phase II trial of gemcitabine/cisplatin/s1 for inoperable biliary tract cancer
Chemotherapy for the patients with inoperable biriary tract cancer
Japan |
Birialy tract cancer
Hematology and clinical oncology | Hepato-biliary-pancreatic surgery |
Malignancy
NO
To evaluate the efficacy of gemcitabine/cisplatin/s1 therapy for inoperable biliary tract cancer.
Efficacy
Overall survival, Response rate, Disease control rate, one-year survival rate, Tumor marker
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Gemcitabine is i.v. administered at a dose of 1000 mg/m2 for 30 min on days 1,8 of each 21-day cycle.
Cisplatin is i.v. administered at a dose of 25 mg/m2 for 120 min on days 1,8 of each 21-day cycle.
TS-1 is administered orally 2 consecutive weeks every 3 weeks.
TS-1 is administered orally on alternate days from day1.
Dose of TS-1 per day
BSA
<1.25 m2 80 mg/day
1.25-1.5 m2 100 mg/day
>=1.5 m2 120 mg/day
20 | years-old | <= |
80 | years-old | > |
Male and Female
1)The patients with inoperable advanced biliary tract cancer including intrahepatic cholangiocarcinoma and ampullary carcinoma diagnosed by pathologically methods or graphically visualizes examination Patients with post-operative recurrent is excluded)
2)Patients of age =>20 and 80>
3)Patientswith Eastern Chemotherapy Oncology Group (ECOG) performance status of 0,1
4)Life expectancy more than 3 months
5)Hemoglobin >=9.0g/dl,
WBC>=3,000/mm3,12,000/mm3,
neutrophils >=1,500/mm3, platelets >=100,000/mm3,
AST/ALT </=100,
Total bilirubin </=2.0 x ULN,
Serum creatinine </=1.0 x ULN,
BUN </=1.0 x ULN,
PaO2 >= 70 torr
Creatinine clearance>=60 ml/min
6)No other treatments, such as radiation or chemotherapy
7)Written informed consent
1)Pulmonary fibrosis or interstitial pneumonia detectable on chest X-ray
2)Active infection
3)Uncontrollable heart disease and myocardial infarction within 6 months
4)Uncontrollable DM
5)Pregnant or lactation women, or women with known or suspected pregnancy
6)History of severe drug allergy
7)Active synchronous or metachronous malignancy
30
1st name | Katsuhiko |
Middle name | |
Last name | Yanaga |
Jikei University school of Medicine
Department of surgery, Division of hepatobiliary pancreatic surgery
105-8461
3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo, Japan
03-3433-1111
kyanaga@jikei.ac.jp
1st name | Tadashi |
Middle name | |
Last name | Uwagawa |
Jikei University school of Medicine
Department of surgery, Division of hepatobiliary pancreatic surgery
105-8461
3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo, Japan
03-3433-1111
uwatadashi@msn.com
Jikei University school of Medicine
Jikei University school of Medicine
Department of surgery
Division of hepatobiliary pancreatic surgery
Self funding
Jikei University school of Medicine IRB
3-19-18 Nishi-Shinbashi, Minato-ku, Tokyo, Japan
03-3433-1111
rinri@jikei.ac.jp
NO
2015 | Year | 04 | Month | 01 | Day |
Unpublished
Open public recruiting
2015 | Year | 04 | Month | 01 | Day |
2015 | Year | 04 | Month | 01 | Day |
2015 | Year | 03 | Month | 25 | Day |
2019 | Year | 03 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019630